Clinical Software in Delaware

E-Scopics is a software-centric ultrasound imaging company pioneering a fully digital, cloud-connected diagnostic platform. Founded by ultrasound and signal processing veterans with 20+ years of industry experience, the company transforms standard consumer devices (PCs, tablets, smartphones) into high-end point-of-care ultrasound diagnostic tools via downloadable software and proprietary smart digital transducers. The core innovation replaces traditional hardware-centric ultrasound with a software-only architecture that leverages ultrafast imaging, raw per-channel RF data capture, and quantitative imaging biomarkers for non-expert users. E-Scopics' first commercial product is Hepatoscope®, an FDA-cleared and CE-marked system designed for point-of-care liver disease assessment (MASLD/MASH risk stratification) that provides liver stiffness and quantitative ultrasound parameters in 4 minutes. The company operates a B2B OEM and research licensing platform, offering foundational ultrasound technology to healthcare and corporate partners. E-Scopics is supported by France 2030 through the €6.7M POCUSI project and has received recognition from Prix Galien MedTech, i-Lab Award, InvestHorizon, and other innovation programs. Primary markets include hepatology, gastroenterology, endocrinology, and primary care. The platform emphasizes accessibility, reproducibility, and clinical quantification for chronic disease surveillance.

Neteera Technologies Ltd. is an FDA-cleared healthcare technology company specializing in contactless remote patient monitoring (RPM) using sub-THz micro-radar on-chip sensors. The company's primary offering is the Neteera System, a ceiling- or wall-mounted device that passively measures vital signs and biomarkers without wearables, cameras, or patient interaction. The system continuously monitors heart rate and pattern analysis, respiratory rate and depth, inhale/exhale ratio, sleep analysis, position changes, motion, and occupancy/exit detection. Designed for use across health systems, hospitals, medical groups, payers, post-acute care facilities, and senior living communities, the technology enables proactive care, early detection of deterioration, and treat-in-place interventions. With over 30,000 deployed devices across 450+ care settings and proven capability to identify cardiac and respiratory events days in advance, Neteera's solution reduces alert fatigue, improves patient compliance, and supports workflow optimization. The system is ISO 13485-certified, HIPAA/HITECH/GDPR compliant, and SOC 2 Type II certified, positioning it as a comprehensive digital health platform for aging populations and clinical monitoring.

Minze Health is a Belgium-based (Antwerp) medical device and digital health company specializing in home-based diagnostics and digital therapeutics for lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), and overactive bladder (OAB). Founded in 2015 and ISO 13485:2016 certified, Minze develops integrated diagnostic and therapeutic solutions that combine in-clinic and home-based uroflowmetry, automated bladder diaries, and evidence-based digital behavioral therapy apps. The Homeflow platform enables smart uroflowmetry for home or in-clinic use with real-time web portal visualization, flow curve analysis, and longitudinal tracking. The Diary Pod is an automated sensor-based bladder diary that captures voiding patterns objectively, reducing patient recall bias. Clinical software includes web portals for providers and mobile apps delivering 13-week personalized therapy programs with lifestyle coaching and pelvic floor training. The company targets urology practices, hospitals, and health systems addressing the estimated 80 million US and 90 million EU adults with LUTS/BPH/OAB. Leadership includes executives with commercial and clinical backgrounds; the medical advisory board comprises senior urologists and urogynecologists from leading US, UK, Canadian, and European institutions. Minze is an AdvaMed member.

Bo&Bo Ltd develops a cloud-based digital physical therapy platform combining motion-sensing hardware and software to deliver gamified, personalized rehabilitation treatment. The platform integrates provider-patient collaboration tools, enabling therapists to create customized exercise programs, track real-time biofeedback through motion sensors, and monitor patient progress through advanced analytics. The system supports hybrid care delivery—blending in-clinic and remote treatment—with features including assessment and analysis modules, performance tracking with pattern analytics, real-time bio-feedback during exercises, cloud-based program storage, progress reporting, and gamification to improve patient engagement and adherence. Designed for physical therapy clinics, rehabilitation centers, and healthcare systems seeking scalable, outcome-focused care models. The platform has been adopted by leading academic institutions (NYU, University of Washington) and supports both individual practitioners and multi-patient environments. Primary market focus is English-speaking markets with digital health infrastructure.

Visibly is a digital health platform that enables optical retailers, contact lens distributors, and e-commerce vision care companies to deliver comprehensive vision care services remotely and in-store. The company operates an anywhere-care platform providing vision prescription renewals, visual acuity testing, prescription verification, and automated contact lens and eyewear fulfillment. Visibly's VDAP (Vision Digital Assessment Platform) product received FDA clearance in 2022, positioning the company as a clinically validated solution for vision screening and prescription management. The platform leverages a nationwide network of licensed eye care providers to review and renew customer prescriptions within 24 hours. Core offerings include at-home vision screening, in-store vision testing for brick-and-mortar locations, video consultations with licensed eye care providers for non-emergency conditions (dry eyes, pink eye, allergies), and automated prescription verification to ensure Contact Lens Rule compliance. Visibly also provides fulfillment automation through pre-built integrations with leading contact lens distributors, labs, and eyewear manufacturers. The technology is delivered via a modern GraphQL API supporting single integration across all products. Visibly serves major e-commerce and retail vision care customers including Next Day Contacts, EZContacts, LensDirect, and ROKA. The platform is HIPAA-compliant and designed for seamless white-label deployment with branded test experiences and customizable workflows.

ORCA Dental AI (operating as CephX) is a cloud-based AI diagnostic software platform specializing in automated dental imaging analysis for orthodontists and maxillofacial imaging centers. The platform provides AI-powered cephalometric tracing and analysis, 3D CBCT segmentation, intraoral scan (IOS) processing, airway volume analysis, and integrated IOS-CBCT stitching. CephX operates as a Software-as-a-Service (SaaS) offering with subscription-based pricing ($79/month for 2D Basic plan) and web-based access requiring no software installation. The company has processed approximately 300,000 cases over 15+ years and maintains FDA clearance and HIPAA compliance. Services include automated landmark detection, teeth and bone segmentation, nerve pathway identification, root absorption detection, and customizable cephalometric analyses (over 100 generic and custom options). The platform supports multiple image formats (DICOM, 2D cephs) with cloud storage, real-time collaboration features, and downloadable reports in PDF, PowerPoint, and JPG formats. Trusted by major dental networks, imaging centers, and individual practitioners globally. The company emphasizes medico-legal compliance, continuous data backup, and technical support.

NovaSight Inc. is a pediatric vision care company specializing in eye-tracking technology and data analytics for the digital assessment and treatment of childhood vision disorders. The company develops objective, non-invasive vision screening and treatment platforms designed for children, leveraging optical infrared sensors that track gaze position 90 times per second combined with proprietary artificial intelligence and big data analytics. NovaSight's primary products include CureSight, a remote digital amblyopia (lazy eye) treatment system, and TrackSight, a myopia management and prevention platform. Both solutions utilize ActiveSight™ proprietary glasses with remote-controlled occlusion and distance/tilt measurement capabilities. The technology eliminates reliance on patient cooperation or operator skill variability, delivering greater accuracy and repeatability than traditional vision assessment methods. Products are designed as child-friendly, entertaining activities that reduce chair time and assessment duration while providing objective clinical insights. The company positions its solutions for ophthalmologists, optometrists, and pediatric eye-care providers globally, with particular focus on pediatric populations. Core technological assets include eye-tracking sensors, proprietary active glasses, AI-driven analytics platforms, and vision population norm databases. The company engages with major professional conferences including AAPOS (American Academy of Pediatric Ophthalmology and Strabismus) annual meetings, indicating clinical validation within the pediatric ophthalmology specialty.

Solvemed Inc. develops PuRe™ Pupillometer, a smartphone-based FDA Class I medical device for objective pupillary assessment in critical care settings. The device employs computational pupillometry to measure pupil size and reactivity with superior accuracy across varying ambient light conditions—addressing a key limitation of conventional infrared pupillometers, which show significant measurement variability in different lighting environments. The PuRe™ score is a lighting-invariant metric derived from exposure-corrected pupillary parameters and is openly published for research benefit. The software integrates securely with major hospital EMR systems (Epic, Oracle, Athena, Meditech, Allscripts, eClinicalWorks) via HIPAA-compliant cloud infrastructure with SOC2 certification. The solution eliminates disposable costs and hardware logistics while providing immediate EMR data upload. Clinical collaborations span Emory Healthcare, NHS Oxford, Harvard-affiliated institutions, and UK research centers. Designed for neuro-ICU, medical-ICU, cardiac-ICU, surgical-ICU, trauma centers, stroke units, and emergency departments. No hardware required; operates on iOS devices with Face ID authentication. The device enables standardized, reproducible neurological assessment comparable to automated vital-sign measurement.

Quest Diagnostics is a large-scale clinical laboratory services provider operating 2,000+ patient service centers across the United States. The company performs over 200 million laboratory tests annually across all patient demographics. Quest offers a comprehensive portfolio of 3,500+ laboratory tests including cardiology markers (Lp(a), ApoB, LDL-C), hematology, biochemistry, genetic testing, prenatal diagnostics (noninvasive prenatal testing, maternal serum screening), and oncology screening. The company serves patients, healthcare professionals, health plans, hospitals, health systems, employers, and life sciences/biopharma organizations. Quest operates significant laboratory automation infrastructure with ongoing modernization efforts and provides IT solutions including Quanum Lab Services Manager for healthcare professionals and healthcare systems. The company recently launched Quest AI Companion, a patient-facing digital tool within MyQuest that provides simplified explanations of lab results. Quest Diagnostics operates a B2B laboratory network model serving as a reference laboratory for hospitals and health systems, providing billing and coding support, and offering population health and workforce health solutions. The organization adheres to clinical laboratory standards and regulatory requirements for laboratory-developed tests.